The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination

Phase 1

Active, not recruiting

• Conditions: Yellow Fever

• Registration Number: NCT04269265
• Lead Sponsor: University of Minnesota

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-2-11
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Inclusion Criteria:<br><br> - No contraindication to Yellow Fever vaccine (immunosuppressed for any reason or on<br> an immunosuppressive drug where a live virus vaccine is contraindicated).<br><br> - If female of childbearing age must agree to contraception for one month following<br> administration of the vaccination.<br><br>Exclusion Criteria:<br><br> - History of yellow fever or previous vaccination for yellow fever<br><br> - Known bleeding disorder<br><br> - Prior surgery complicated by clotting abnormality<br><br> - Psychiatric or behavioral disorder that, in the opinion of the investigator, will<br> make it difficult for the participant to complete the study<br><br> - History of acute hypersensitivity reaction to any component of the vaccine<br> (including gelatin, eggs, egg products, or chicken protein).<br><br> - Thymus disorder associated with abnormal immune function<br><br> - Immunosuppression from any of the following: HIV infection or AIDS, malignant<br> neoplasms, primary immunodeficiencies, transplantation, transplantation,<br> immunosuppressive or immunomodulatory therapy (corticosteroids, alkylating agents,<br> antimetabolites, TNF inhibitors, IL-1 blocking agents, monoclonal antibodies<br> targeting immune cells), previous radiation therapy.<br><br> - Pregnant or breastfeeding at the time of vaccination.<br><br> - Planning to conceive within 28 days of enrollment and vaccination with the yellow<br> fever vaccine.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Peak Neutralizing Antibody Titer